NEW
Stock Screener with Intrinsic Value
Summit Therapeutics Inc. (SMMT)
Last Price$23.60.4%
Market Cap$17.1B
LTM P/E
(87.0x)
EPS growth
(42.2%)
PEGY
2.1x
Peter Lynch Fair Value
$11.4
Overvalued (Peter Lynch formula)
(51.5%)
Stock quality
7/10
Great
SMMT Peter Lynch Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
SMMT EPS growth & Dividend Yield
Crunching data... Almost there!
SMMT vs Peer Set: Peter Lynch Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for SMMT
Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Summit Therapeutics Inc. fair value by Peter Lynch formula?
As of Jan 28, 2025, Summit Therapeutics Inc.'s fair value using the Peter Lynch formula is $11.4 per share. The current price of $23.6 suggests Summit Therapeutics Inc. may be overvalued by this metric.
What is Summit Therapeutics Inc. Price to Earnings (P/E) ratio?
As of Jan 28, 2025, Summit Therapeutics Inc.'s P/E ratio is (87.0x). This is calculated by dividing the current share price of $23.6 by the Earnings per Share (EPS) for the trailing twelve months, which is ($0.3). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is Summit Therapeutics Inc. earnings per share (EPS)?
Summit Therapeutics Inc. earnings per share (EPS) for the twelve months ending Jan 28, 2025, was ($0.3), a (42.2%) growth year-over-year.